IMO---I don't read a lot into AGM items, except for buyback plan (if executed). The EU Supervisory Board structure is ok, but clunky in my view. Buying back stock that values your technology at zero is sound, IF you are confident of cash availability going forward...... i.e. macro call on the financing window and confidence in your pipeline/partners. As far as BMY, I doubt they are staying up nights worrying about their cash out on the shares. The behavior of big pharma in the arena of developmental technology investment is a whole lot different than our speculation. I think we see a re-pricing here for deferred success based on recent events. My expectation is for slower pain, but pain indeed, with no immediate catalyst visible to shake the negative sentiment. Could be a major holder is clearing out this quarter??? I suppose we'll see soon enuf.
Epic collapse of share price for QURE. Trading at cash on hand valuation. Of course burn makes that a moving target...... Seems their chosen compounds are being outflanked by competition. Still like their technology, and if ONCE stumbles with their Padua varient for HEM B this will be a rocket. More likely though is more pain, albeit slower...sector performer. (unless their is more cooking with partners than we can see). Crazy underwater here.